GO
Loading...

Biogen Idec Inc

More

  • *Wall Street pares gains after late biotech selloff. NEW YORK, March 28- Global equity markets ended higher on Friday but U.S. stocks sharply pared gains after a late selloff in biotechnology shares, while euro zone government bond yields fell on renewed bets the European Central Bank will ease policy next week.

  • *Momentum stocks still in focus; Netflix falls. NEW YORK, March 28- U.S. stocks ended up on Friday but off their session highs as a late afternoon selloff in the biotechnology sector weighed on the overall market. The Nasdaq Composite Index fell nearly 3 percent for the week, marking its worst week since October 2012.

  • *Momentum stocks still in focus; Netflix falls. NEW YORK, March 28- U.S. stocks sharply pared gains by late Friday afternoon on Friday, with the Nasdaq briefly turning negative, led by a decline in the biotechnology sector. Gilead Science shares were off 3.3 percent at $69.03 and Biogen Idec shares were down 4.1 percent at $297.

  • Cramer: Vicious trend could hit good stocks Tuesday, 25 Mar 2014 | 6:43 PM ET

    There’s a vicious new trend underway in the market and Cramer says stocks of perfectly good companies could take a big hit.

  • *Walgreen, McCormick shares rally after results. NEW YORK, March 25- U.S. stocks sharply trimmed gains by midday on Tuesday as many of the market's momentum stocks turned negative. So-called momentum stocks fell sharply near midday, including Netflix, down 3 percent at $367.50, and First Solar Inc, down 4 percent at $70.93.

  • Biogen Idec CEO talks pipeline, keys to growth Friday, 21 Mar 2014 | 6:48 PM ET
    Biogen Idec

    Biogen CEO George Scangos talks about future growth opportunities at the company on CNBC's "Fast Money."

  • *Nike shares fall after results. Biogen Idec Inc, down 8.2 percent at $318.53, and Gilead Sciences Inc, down 4.6 percent at $72.07, were the two biggest drags on the S&P 500. The Nasdaq biotech index fell 4.4 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • *Nike shares fall after results, Tiffany rises. Biogen Idec Inc, down 8 percent to $319.14, and Gilead Sciences Inc, down 3.7 percent to $72.74, were the biggest drags on the S&P 500. The Nasdaq biotech index fell 3.5 percent.

  • Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide. It is expected to be approved in the United States later this year.

  • March 21- Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix. Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide. It is expected to be approved in the United States later this year.

  • March 18- Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application. Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies. Biogen shares closed at $345.60 on Monday on the Nasdaq.

  • Midday movers: General Motors, Yahoo & More Monday, 17 Mar 2014 | 12:15 PM ET

    Take a look at some of Monday's midday movers.

  • Early movers: GMCR, BHI, SHLD, TM & more Monday, 17 Mar 2014 | 7:52 AM ET
    Sears' flagship store in Chicago.

    Some of the names on the move ahead of the open.

  • Lightning Round: GE, Biogen & More Friday, 14 Mar 2014 | 6:39 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Clouds gather in markets; no storm forecast yet Wednesday, 12 Mar 2014 | 10:46 AM ET

    There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.

  • Midday movers: Pandora, Kroger, RadioShack & More Thursday, 6 Mar 2014 | 12:26 PM ET
    Speaker wall at a Radio Shack concept store in New York City.

    Some of Thursday's midday movers:

  • FRANKFURT, March 6- Germany's Merck KGaA, the worlds largest maker of liquid crystals for display screens, reported an unexpected rise in underlying profits on Thursday as the benefits of its cost cutting campaign more than offset the impact of weaker foreign currency exchange rates.

  • Five themes Putin can’t trample into submission Tuesday, 4 Mar 2014 | 6:00 PM ET

    Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?

Most Popular Video

Thursday, 17 Apr 2014 | 4:00 PM ET

CNBC's Patti Domm discusses the key market movers to watch for next week.

Thursday, 17 Apr 2014 | 2:41 PM ET

Both Monaco and Miami have soaring real estate prices. CNBC's Robert Frank reports the super rich are really transforming Miami.

Thursday, 17 Apr 2014 | 1:07 PM ET

In a groundbreaking paper, Gauti Eggertsson of Brown University has shown that secular stagnation is possible. Now he explains why it could happen in the United States. With CNBC's Jackie DeAngelis and the Futures Now Traders.